RET and cancer: Rare targets such as NTRK, NRG1 (neuregulin 1) and RET (rearranged during transfection) fusions are becoming increasingly relevant for clinical management Pan-Cancer and efforts to unify biomarker epidemiology data is critical from a public health perspective to understand the potential impact of novel targeted therapies at a population level, and ensure these patients are identified efficiently.